1. Home
  2. GRNQ vs IMNN Comparison

GRNQ vs IMNN Comparison

Compare GRNQ & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Greenpro Capital Corp.

GRNQ

Greenpro Capital Corp.

N/A

Current Price

$1.80

Market Cap

16.6M

Sector

Technology

ML Signal

N/A

Logo Imunon Inc.

IMNN

Imunon Inc.

HOLD

Current Price

$3.55

Market Cap

12.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GRNQ
IMNN
Founded
2013
1982
Country
Malaysia
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.6M
12.5M
IPO Year
2018
1985

Fundamental Metrics

Financial Performance
Metric
GRNQ
IMNN
Price
$1.80
$3.55
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$182.61
AVG Volume (30 Days)
16.4K
78.6K
Earning Date
11-13-2025
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,110,208.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
14.04
N/A
52 Week Low
$0.84
$2.99
52 Week High
$2.50
$41.22

Technical Indicators

Market Signals
Indicator
GRNQ
IMNN
Relative Strength Index (RSI) 56.54 42.77
Support Level $1.67 $3.38
Resistance Level $1.82 $3.88
Average True Range (ATR) 0.09 0.33
MACD -0.00 -0.01
Stochastic Oscillator 66.73 43.81

Price Performance

Historical Comparison
GRNQ
IMNN

About GRNQ Greenpro Capital Corp.

Greenpro Capital Corp operates and provides business solution services to small and medium-sized businesses located in Southeast Asia and East Asia, with a focus on Hong Kong, China and Malaysia, and in Thailand and Taiwan. Its range of services includes cross-border business solutions, record management services, and accounting outsourcing services. Cross-border business services include other services, tax planning, trust and wealth management. Its segments include Service business engaged in the provision of corporate advisory and business solution services; Real estate business segment engaged in trading or leasing of commercial real estate properties in Hong Kong and Malaysia; and Digital business segment engaged in provision of digital platform and trading of digital assets.

About IMNN Imunon Inc.

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

Share on Social Networks: